Clinical trials: Relapsed or Refractory Multiple Myeloma
Relapsed and/or Refractory Multiple Myeloma
A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma
This will be a Phase 1 Open-Label, dose escalation of MT-0169 (an Engineered toxin body (ETB) in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT04017130
- Testing
- MT-0169
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- Molecular Templates, Inc.
Multiple Myeloma, Chronic Lymphocytic Leukaemia
A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma
The aim of this study is to determine the safety, tolerability and dose-limiting toxicities of KW-2478 and to determine the Maximum Tolerated Dose and recommended Phase II dose for patients with relapsed/refractory MM, CLL or…
- Conditions
- Multiple Myeloma, Chronic Lymphocytic Leukaemia, B-cell Non-Hodgkin's Lymphoma
- Trial name
- NCT00457782
- Testing
- KW-2478
- Where
- 6 sites in United Kingdom
- Volunteers
- 27 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Relapsed or Refractory Multiple Myeloma
A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
This was a multicenter, open-label, single-arm phase 3B study of the combination lenalidomide plus pulse high-dose dexamethasone.
- Trial name
- NCT00478777
- Testing
- Lenalidomide, dexamethasone
- Where
- 48 sites in Germany
- Volunteers
- 150 people
- Sponsor
- Celgene Corporation
Multiple Myeloma
Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
The purpose of this study is to investigate the anti-myeloma effect of panobinostat given at two different doses (10 mg and 20 mg oral) in combination with carfilzomib (20/56 mg/m2 i.v.) and low dose dexamethasone (20 mg oral) vs…
- Trial name
- PANORAMA-5 (NCT02756663)
- Testing
- panobinostat (capsules), carfilzomib (infusion), dexamethasone (tablets)
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use
To understand the safety and efficacy of Revlimid® 5 mg Capsules (hereinafter referred to as Revlimid) in patients with "relapsed or refractory multiple myeloma" (hereinafter referred to as "relapsed or refractory MM") who have…
- Trial name
- NCT02922543
- Where
- Japan
- Volunteers
- 361 people
- Sponsor
- Celgene
Multiple Myeloma
Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma
A Phase 1, open-label, dose escalation, multi-center study in patients who have been diagnosed with multiple myeloma and who have relapsed or have refractory/relapsed disease after treatment with at least 2 prior therapies.
- Trial name
- NCT00609817
- Testing
- GCS-100, Bortezomib/Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- La Jolla Pharmaceutical Company
Multiple Myeloma
Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
The primary objective of the study is to determine the maximum tolerated dose (MTD) of CEP-18770 in combination with lenalidomide and dexamethasone in participants with relapsed or refractory multiple myeloma.
- Trial name
- NCT01348919
- Testing
- CEP-18770, Lenalidomide, Dexamethasone
- Where
- 8 sites in United States, New Zealand
- Volunteers
- 11 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
AML/MDS, CD33 Expressing Hematological Malignancies
SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS
This is an open-label study of the safety, biodynamics, and anti-cancer activity of SENTI-202 (an off-the-shelf logic gated CAR NK cell therapy) in patients with CD33 and/or FLT3 expressing blood cancers, including AML and MDS.
- Conditions
- AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies
- Trial name
- NCT06325748
- Testing
- SENTI-202
- Where
- 8 sites in United States, Australia
- Volunteers
- 21 people
- Sponsor
- Senti Biosciences
Relapsed or Refractory Multiple Myeloma
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
The purpose of the study is to evaluate safety and tolerability of the combination of cevostamab plus elranatamab and also determine the recommended Phase II regimen (RP2R) for the study treatment.
- Trial name
- NCT05927571
- Testing
- Cevostamab, Elranatamab, Tocilizumab
- Where
- 14 sites in Australia, Israel and 1 more
- Volunteers
- 120 people
- Sponsor
- Genentech, Inc.
Lymphoma, Multiple Myeloma
A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies
The purpose of this clinical trial is to learn about how safe and tolerable is the study medicine (called maplirpacept (PF-07901801)) when taken for the treatment of lymphoma or multiple myeloma (a type of cancer that affects…
- Trial name
- NCT05567887
- Testing
- maplirpacept (PF-07901801)
- Where
- 4 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Pfizer
Multiple Myeloma
Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma
This is a Phase I/IIa clinical trial to identify the maximum tolerated dose of atiprimod and to evaluate the safety of atiprimod in patients with refractory or relapsed multiple myeloma.
- Trial name
- NCT00086216
- Testing
- Atiprimod
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Callisto Pharmaceuticals
Relapsed or Refractory Multiple Myeloma
Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients
The purpose of this expanded access treatment protocol is to provide patients access to teclistamab prior to market authorization.
- Trial name
- NCT05463939
- Testing
- Teclistamab
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
This study will compare the efficacy of PS-341 versus high dose dexamethasone.
- Trial name
- NCT00048230
- Testing
- bortezomib
- Where
- 93 sites in United States, Austria and 11 more
- Volunteers
- 620 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Hematological Malignancies
A Study of TQB3820 in Patients With Hematological Malignancies
TQB3820 is a novel cereblon-modulating agent. Upon binding to cereblon, a substrate receptor in the cullin4 E3 ligase complex, TQB3820 promotes recruitment, ubiquitination, and subsequent proteasomal degradation of the…
- Trial name
- NCT05020639
- Testing
- TQB3820 tablets
- Where
- 2 sites in China
- Volunteers
- 116 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Multiple Myeloma
Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
The purpose of this study is to determine 1) the safety and tolerability of multiple intravenous doses of anti-CXCR4 (BMS-936564) as monotherapy and as combination, and 2) the maximum tolerated dose (MTD) of BMS-936564 in…
- Trial name
- NCT01359657
- Testing
- Anti-CXCR4 (BMS-936564), Lenalidomide, Dexamethasone
- Where
- 4 sites in United States
- Volunteers
- 46 people
- Sponsor
- Bristol-Myers Squibb
Relapsed/Refractory Multiple Myeloma
Clinical Study on Evaluating the Safety and Effectiveness of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Third-line or Above Treatment
This study is a single-arm, single-center clinical study, with the main purpose of IIT clinical trials to evaluate the safety and initial efficacy of BCMA-GPRC5DCAR-T cells in subjects with relapsed/refractory multiple myeloma…
- Trial name
- r/r MM (NCT07195617)
- Testing
- BCMA-GPRC5D CART
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd
Waldenstrom Macroglobulinemia, Multiple Myeloma
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Part A of this study evaluates iopofosine I 131 (CLR 131) in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic…
- Conditions
- Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- CLOVER-WaM (NCT02952508)
- Testing
- Iopofosine I 131 single dose, Iopofosine I 131 multiple dose, Iopofosine I 131 fractionated dose
- Where
- 52 sites in United States, Australia and 9 more
- Volunteers
- 120 people
- Sponsor
- Cellectar Biosciences, Inc.
Multiple Myeloma
A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
The purpose of this study is to evaluate the efficacy and safety of alnuctamab compared to standard of care regimens in participants with relapsed or refractory multiple myeloma (RRMM).
- Trial name
- ALUMMINATE (NCT06232707)
- Testing
- Alnuctamab, Pomalidomide, Daratumumab
- Where
- 170 sites in United States, Argentina and 25 more
- Sponsor
- Celgene
Relapsed or Refractory Multiple Myeloma (RRMM)
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing F182112 with Standard of Care in Patients with Relapsed or Refractory Multiple Myeloma
- Trial name
- NCT07579234
- Testing
- F182112 single-agent, Pomalidomide + Bortezomib + Dexamethasone (PVd) or Selinexor + Bortezomib + Dexamethasone (SVd)
- Where
- China
- Volunteers
- 261 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Multiple Myeloma
Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
To explore whether Elotuzumab dose administration over approximately 60 minutes is feasible and safe.
- Trial name
- NCT02159365
- Testing
- Elotuzumab, Lenalidomide, Dexamethasone
- Where
- 29 sites in United States
- Volunteers
- 84 people
- Sponsor
- Bristol-Myers Squibb